A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2339345.
Status:
Completed
Trial end date:
2012-07-30
Target enrollment:
Participant gender:
Summary
This is a study of the sodium channel inhibitor, GSK2339345. Cohort 1 will assess the safety,
tolerability and PK of single ascending doses of GSK2339345 administered via an aqueous
droplet inhaler in healthy subjects. Cohort 2 will assess the safety, tolerability, and PK of
repeat doses of GSK2339345 administered four times a day for two consecutive days via an
aqueous droplet inhaler.